VARENICLINE ( DrugBank: Varenicline )

---

3 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	5
18	Spinocerebellar degeneration	1
53	Sjogren syndrome	1

6. Parkinson disease

---

Clinical trials : 2,307 /  Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04403399 (ClinicalTrials.gov)	June 29, 2017	21/5/2020	Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])	Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiment 3 - Project #3	Parkinson's Disease	Drug: Varenicline;Drug: Placebo	University of Michigan	NULL	Completed	45 Years	N/A	All	34	Phase 2	United States
2	NCT02933372 (ClinicalTrials.gov)	October 5, 2015	6/4/2016	Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3	Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Projects #3	Parkinson's Disease	Drug: Varenicline;Radiation: [18-Fluorine] Flubatine PET Scan;Other: Evaluation by Investigator	University of Michigan	NULL	Completed	45 Years	N/A	All	25	Phase 2	NULL
3	NCT02473562 (ClinicalTrials.gov)	May 2013	12/6/2015	Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's Disease	Varenicline, a Partial Nicotinic Receptor Agonist for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease: a Placebo-controlled Cross-over Pilot Study	Parkinson's Disease	Drug: Varenicline;Drug: Placebo (for varenicline)	VU University Medical Center	Centre for Human Drug Research, Netherlands	Terminated	N/A	N/A	All	22	Phase 4	Netherlands
4	EUCTR2012-001530-34-NL (EUCTR)	09/08/2012	09/08/2012	Vareniciline treatment for Excessive Daytime Sleepiness in Parkinson’s Disease	Varenicline, a partial nicotinic receptor agonist for the treatment of Excessive Daytime Sleepiness in Parkinson’s Disease: a placebo-controlled cross-over study - Vareniciline for Excessive daytime Sleepiness in PArkinson’s disease (VESPA)	Idiopathic Parkinson's disease MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Champix INN or Proposed INN: VARENICLINE Other descriptive name: VARENICLINE TARTRATE	VU University Medical Center	Center Human Drug Research	Not Recruiting			Female: yes Male: yes	32	Phase 3	Netherlands
5	NCT01341080 (ClinicalTrials.gov)	December 28, 2010	21/4/2011	Varenicline for Gait and Balance Impairment in Parkinson Disease	Varenicline for the Treatment of Postural and Gait Dysfunction in Parkinson Disease	Parkinson Disease	Drug: Varenicline;Drug: Sugar pill	Rush University Medical Center	NULL	Completed	40 Years	90 Years	All	40	Phase 2	United States

Back to top

18. Spinocerebellar degeneration

---

Clinical trials : 76 /  Drugs : 98 - (DrugBank : 31) / Drug target genes : 44 - Drug target pathways : 65

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000011560	2013/08/30	26/08/2013	Trial of varenicline (Champix) for the treatment of spinocerebellar degeneration	Trial of varenicline (Champix) for the treatment of spinocerebellar degeneration - Varenicline trial for SCD	spinocerebellar degeneration (SCD)	[High-dose Group] Oral administration of varenicline 1-7 days 0.5 mg/day 8-14 days 1.0mg/day 15-21 days 1.5mg/day 22-56 days 2.0 mg/day 57-63 days 1.0 mg/day 64-70 days 0.5 mg/day 71-84 days Wash-out period 85-154 days 0.5 mg/day [Low-dose Group] Oral administration of varenicline 1-70 days 0.5 mg/day 71-84 days Wash-out period 85-91 days 0.5 mg/day 92-98 days 1.0mg/day 99-105 days 1.5mg/day 106-140 days 2.0 mg/day 141-147 days 1.0 mg/day 148-154 days 0.5 mg/day	Niigata University	NULL	Recruiting	20years-old	Not applicable	Male and Female	40	Phase 1,2	Japan

53. Sjogren syndrome

---

Clinical trials : 305 /  Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05700422 (ClinicalTrials.gov)	February 2023	14/1/2023	Nasal Spray Study in Sjogren's Dry Eye Disease	A Single-arm Investigator Initiated Study to Evaluate the Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease in Subjects With Sjogren's Syndrome	Sjogren's Syndrome;Dry Eye	Drug: Varenicline Nasal Spray	University of Pennsylvania	Oyster Point Pharma, Inc.	Not yet recruiting	18 Years	N/A	All	40	Phase 4	NULL

Back to top